Natural Products in Internal Diseases: From Preclinical Research to Clinical Translation

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: 15 August 2025 | Viewed by 164

Special Issue Editors


E-Mail Website
Guest Editor
Postgraduate Program in Pharmaceutical Sciences, Department of Pharmacy, Center for Studies in Bio-Pharmacy, Federal University of Paraná, Curitiba 80210-170, Brazil
Interests: pharmacokinetics; drug monitoring; health technology assessment; artificial intelligence; clinical pharmacology; phytotherapy; natural products
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Center for Studies in Bio-Pharmacy, Postgraduate Program in Pharmaceutical Sciences, Department of Pharmacy, Federal University of Paraná, Curitiba 80210-170, PR, Brazil
Interests: drug delivery systems; pharmacokinetics; health technology assessment; drug safety; clinical pharmacology; natural products
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor Assistant
Postgraduate Program in Pharmaceutical Sciences, Department of Pharmacy, Center for Studies in Bio-Pharmacy, Federal University of Paraná, Curitiba 80210-170, Brazil
Interests: drug delivery systems; pharmacokinetics; drug monitoring; health technology assessment; drug safety; natural products
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue focuses on exploring natural products and their therapeutic potential in the management and treatment of internal diseases. Natural products have long been a rich source of bioactive compounds with diverse pharmacological properties, offering promising avenues for addressing unmet medical needs in conditions such as cardiovascular diseases, diabetes, autoimmune disorders, gastrointestinal conditions, and respiratory illnesses.

We invite researchers to submit original research articles, reviews, systematic reviews, and case studies on topics including, but not limited to, the following: 

  • The isolation and characterization of bioactive compounds from natural sources;
  • The mechanisms of action of therapeutic effects of natural products in internal diseases;
  • The development of novel formulations and drug delivery systems for natural compounds;
  • Preclinical and clinical studies evaluating the efficacy and safety of natural products;
  • Pharmacokinetics, pharmacodynamics, and toxicity profiles of natural compounds;
  • The synergistic effects of natural products with conventional therapies;
  • Studies leveraging artificial intelligence for drug discovery and the optimization of natural product therapies;
  • The evaluation of phytotherapeutics in the context of traditional practices and their integration into evidence-based medicine.

Contributions addressing innovative methodologies and translational approaches in the use of natural products and phytotherapeutics are particularly encouraged, and we also welcome systematic reviews evaluating the state of evidence in this area. This Special Issue aims to provide a comprehensive understanding of the role of natural products in modern medicine, promoting their application from bench to bedside.

Prof. Dr. Roberto Pontarolo
Dr. Luana Mota Ferreira
Guest Editors

Dr. Raul Edison Luna Lazo
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • natural products
  • internal diseases
  • cardiovascular diseases
  • diabetes
  • autoimmune disorders
  • gastrointestinal conditions
  • respiratory illnesses

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

22 pages, 1862 KiB  
Review
Biological Activities of Mikania glomerata and Mikania laevigata: A Scoping Review and Evidence Gap Mapping
by Thaís Pelegrin Garcia, Daniela Gorski, Alexandre de Fátima Cobre, Raul Edison Luna Lazo, Gustavo Bertol, Luana Mota Ferreira and Roberto Pontarolo
Pharmaceuticals 2025, 18(4), 552; https://doi.org/10.3390/ph18040552 - 9 Apr 2025
Viewed by 71
Abstract
Background/Objectives: The species Mikania glomerata and Mikania laevigata are commonly referred to as guaco. Their preparations are used in traditional Brazilian medicine, mainly to address respiratory conditions affecting the upper airways. Considering the wide popular use of this species, the present study [...] Read more.
Background/Objectives: The species Mikania glomerata and Mikania laevigata are commonly referred to as guaco. Their preparations are used in traditional Brazilian medicine, mainly to address respiratory conditions affecting the upper airways. Considering the wide popular use of this species, the present study aims to survey the biological activities of guaco that have already been proven in the literature and to generate an evidence gap map for these biological activities. Methods: A scoping review was conducted using the electronic databases PubMed, Scopus, and Web of Science (7 October 2024), which included all studies that have evaluated the biological activities of the leaves of the M. glomerata or M. laevigata species. Results: A total of 57 studies (31 assessed only M. glomerata, 17 assessed only M. laevigata, and 9 assessed both species) evaluating 38 different biological activities demonstrated that preclinical studies reported 23 biological activities for M. glomerata and 24 for M. laevigata. The most extensively researched activity for both species is their anti-inflammatory properties, which have been associated with their efficacy in treating bronchoconstriction and their popular uses as an antiophidic agent. The gap map illustrates the lack of evidence to support the biological activity of these species, which may explain some of their popular uses, such as their use as expectorants, antipyretics, for arthritis, rheumatism, neuralgia, and as an antisyphilitic. Conclusions: Considering these findings, there is a clear need for further studies to evaluate the activity of these species for these purposes, mainly through clinical studies. Full article
Show Figures

Figure 1

Back to TopTop